Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer.

BACKGROUND In advanced colorectal cancer, K-Ras somatic mutations predict resistance to mAbs targeting epidermal growth factor receptor (EGFR). Relationships between K-Ras mutations and EGFR status have not been examined so far. We analyzed relationships between K-Ras mutations and EGFR tumoral status based on EGFR germinal polymorphisms, gene copy number and expression. METHODS Eighty colorectal tumors (stage 0-IV) and 39 normal mucosas were analyzed. K-Ras mutations at codons 12 and 13 were detected by a sensitive enrichment double PCR-restriction fragment length polymorphism (RFLP) assay. EGFR gene polymorphisms at positions -216G>T, -191C>A and 497Arg>Lys were analyzed (PCR-RFLP), along with CA repeat polymorphism in intron 1 (fluorescent genotyping) and EGFR gene copy number (PCR amplification). EGFR expression was quantified by Scatchard binding assay. RESULTS The number of EGFR high-affinity sites, dissociation constant (Kd), gene copy number, intron 1, -216G>T, -191C>A or 497Lys>Arg genotypes was not different between K-Ras-mutated or K-Ras-non-mutated tumors. No relationship was observed between any of the analyzed EGFR genotypes and EGFR expression. EGFR expression was not related to gene copy number. EGFR gene copy number in tumor and normal tissue was not correlated. The mean value of the tumor/normal mucosa gene copy number ratio was 1.16. CONCLUSIONS Present data clearly show that EGFR status is independent of K-Ras mutations in colorectal tumors.

[1]  Neal J Meropol,et al.  Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  C. Létoublon,et al.  EGFR in colorectal cancer: more than a simple receptor. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Horst Buerger,et al.  Distinct amplification of an untranslated regulatory sequence in the egfr gene contributes to early steps in breast cancer development. , 2003, Cancer research.

[4]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  T. Shibata,et al.  Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[7]  W. Gerald,et al.  Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study , 2005, Modern Pathology.

[8]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[9]  Neal J Meropol,et al.  Targeting signal transduction pathways in colorectal cancer--more than skin deep. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Moroni,et al.  Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Igor Goryanin,et al.  The impact of the regulatory design on the response of epidermal growth factor receptor‐mediated signal transduction towards oncogenic mutations , 2007, The FEBS journal.

[12]  M. Korc,et al.  A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Silvia Benvenuti,et al.  Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. , 2007, Cancer research.

[14]  A. Lièvre,et al.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Schmid,et al.  Automated real-time PCR to determine K-ras codon 12 mutations in non-small cell lung cancer: comparison with immunohistochemistry and clinico-pathological features. , 2003, International journal of oncology.

[16]  A. D. Dei Tos The biology of epidermal growth factor receptor and its value as a prognostic/predictive factor. , 2007, The International journal of biological markers.

[17]  P. Laurent-Puig,et al.  K-Ras Mutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive Fluoropyrimidine Therapy , 2008, Clinical Cancer Research.

[18]  T. Hunter,et al.  Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors , 1989, The Journal of cell biology.

[19]  Silvia Benvenuti,et al.  Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. , 2005, The Lancet. Oncology.

[20]  E. Cook,et al.  A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. , 2005, Cancer research.

[21]  Y H Xu,et al.  Structure and localization of genes encoding aberrant and normal epidermal growth factor receptor RNAs from A431 human carcinoma cells , 1985, Molecular and cellular biology.

[22]  D. Khayat,et al.  Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer. , 2008, Critical reviews in oncology/hematology.

[23]  T. Frebourg,et al.  Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy , 2007, British Journal of Cancer.

[24]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[25]  J. Isola,et al.  Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence—first results of an inter‐ethnic breast cancer study , 2004, The Journal of pathology.

[26]  S. Groshen,et al.  Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  K. Zänker,et al.  Modulation of Epidermal Growth Factor Receptor Gene Transcription by a Polymorphic Dinucleotide Repeat in Intron 1* , 1999, The Journal of Biological Chemistry.

[28]  Suzanne Schubbert,et al.  Hyperactive Ras in developmental disorders and cancer , 2007, Nature Reviews Cancer.

[29]  N. Magné,et al.  Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  Manuel Hidalgo,et al.  An Epidermal Growth Factor Receptor Intron 1 Polymorphism Mediates Response to Epidermal Growth Factor Receptor Inhibitors , 2004, Cancer Research.

[31]  J. Laborda,et al.  36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. , 1991, Nucleic acids research.

[32]  Xiaoling Li,et al.  Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study , 2004, Modern Pathology.

[33]  Manuel Hidalgo,et al.  Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  E. Cook,et al.  Relationship of EGFR Mutations, Expression, Amplification, and Polymorphisms to Epidermal Growth Factor Receptor Inhibitors in the NCI60 Cell Lines , 2007, Clinical Cancer Research.